Prof. Paolo Ghia discusses the results of a matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia
Prof. Paolo Ghia (Università Vita Salute San Raffaele, Italy)
This HematoTalk is brought to you by the publisher of the Belgian Journal of Hematology (BJH) in partnership with AstraZeneca.
NS ID XL-3698-Revision date 09/2023-LB
Local code 1417